-Rapid generation and validation of three distinct and highly specific Affimer binders to Zika virus within just thirteen weeks of receiving the virus target.
-The Affimer reagents bind a protein called NS1 which is diagnostic of the early, acute stage of Zika infection and for which no validated antibody is available.
-Highlights the potential of Affimer technology to support global rapid response for novel point-of-care diagnostics and health screening.
Avacta Group plc (AIM: AVCT) (“Avacta” or “the Group”), the developer of Affimer® biotherapeutics and research reagents, today announced it has identified three Affimer proteins capable of binding to a recombinant form of a secreted Zika virus NS1 protein (Non-Structural protein 1), which is diagnostic of Zika virus infection at the early, acute stage. These Affimer binders were identified and characterised within just thirteen weeks of receiving the virus target and have the potential to be developed into new rapid point-of-care ...
